Is This Reagent an ASR or a Finished IVD?

What This Reagent-Identity Worksheet Marks

When medical device regulatory affairs (RA) and quality assurance (QA) professionals evaluate a commercially distributed chemical or biological reagent SKU in the United States, they often confront conflicting operational demands. Marketing teams may seek to highlight biomarker utility, clinical laboratories demand flexible building blocks for laboratory-developed tests (LDTs), and manufacturing teams must determine whether full design controls and quality system duties apply. The critical regulatory truth is that a single reagent SKU can possess exactly one regulatory identity at a time. It cannot be marketed simultaneously as an Analyte Specific Reagent (ASR), a General Purpose Reagent (GPR), an investigational Research Use Only (RUO) shipment, and a finished In Vitro Diagnostic (IVD) device.

The foundational governing provisions are codified in 21 CFR 864.4020 and 21 CFR 809.30. These regulations establish that an ASR is a restricted device under Section 520(e) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), subject to rigorous limitations on sale, distribution, promotional statements, and container labeling. Misunderstanding these boundaries is not a minor paperwork defect. Restricted-device sale outside 21 CFR 809.30 can misbrand a product under FD&C Act section 502(q). Distributing a device that requires premarket approval or 510(k) notification without that authorization can adulterate under section 501(f) and misbrand under section 502(o). Those clauses are not interchangeable, and this worksheet is not individual legal advice.

This worksheet provides a sequential, decision-tree methodology for RA/QA teams to evaluate any commercially distributed reagent SKU against US Food and Drug Administration (FDA) requirements. Specifically, this worksheet forces an explicit determination across seven core regulatory dimensions:

1. Intended Use and Active Ingredient Characterization: Verifying whether the molecule serves as a single-ligand building block under 21 CFR 864.4020(a) or a non-specific laboratory constituent under 21 CFR 864.4010(a).

2. Absence of Procedural and Performance Claims: Auditing labeling and promotional collateral to confirm that no instructions for use, procedural protocols, or analytical/clinical performance claims are made.

3. Statutory Device Classification: Determining whether the analyte falls under 21 CFR 864.4020(b)(1) Class I (510(k) exempt), 864.4020(b)(2) Class II (special controls for blood banking), or 864.4020(b)(3) Class III (premarket approval for HIV, tuberculosis, or donor screening).

4. Authorized Purchaser Class: Restricting customer eligibility exclusively to the three permitted categories under 21 CFR 809.30(b).

5. Applicability of Carve-Out Relief: Establishing whether 21 CFR 809.30(g) and 21 CFR 864.4020(a)(1)–(2) lift labeling and advertising duties for sales to IVD manufacturers or nonclinical research organizations.

6. Labeling Family Selection: Applying the exact statutory statement under 21 CFR 809.10(e) rather than finished-IVD labeling (809.10(a)/(b)), investigational statements (809.10(c)(2)), or general laboratory labeling (809.10(d)).

7. Manufacturing Quality System Alignment: Complying with full Part 820 Quality Management System Regulation (QMSR) requirements pursuant to 21 CFR 809.20(b), distinguishing ASR manufacture from the limited records-and-complaints exemption granted to non-sterile GPRs under 21 CFR 864.4010(b) and 21 CFR 820.35.

Mark Intended Use Before Any ASR Statement

Under US medical device law, intended use governs classification, regulatory pathway, and post-market controls. Before examining any label claim, catalog description, or customer agreement, manufacturers must ground their assessment in statutory definitions. Under 21 CFR 809.3(a), an In Vitro Diagnostic (IVD) product is defined as reagents, instruments, and systems intended for use in the diagnosis of disease or other conditions, including a determination of the state of health, in order to cure, mitigate, treat, or prevent disease or its sequelae, intended for use in the collection, preparation, and examination of specimens taken from the human body.

"In vitro diagnostic products are those reagents, instruments, and systems intended for use in the diagnosis of disease or other conditions, including a determination of the state of health, in order to cure, mitigate, treat, or prevent disease or its sequelae. Such products are intended for use in the collection, preparation, and examination of specimens taken from the human body."

IVDs are medical devices under Section 201(h) of the FD&C Act and may also be biological products subject to Section 351 of the Public Health Service (PHS) Act. Within this broad IVD umbrella, 21 CFR 864.4020(a) carves out a highly specific classification identity for Analyte Specific Reagents:

"Analyte specific reagents (ASR's) are antibodies, both polyclonal and monoclonal, specific receptor proteins, ligands, nucleic acid sequences, and similar reagents which, through specific binding or chemical reaction with substances in a specimen, are intended for use in a diagnostic application for identification and quantification of an individual chemical substance or ligand in biological specimens."

When FDA promulgated the ASR final rule in November 1997 (62 FR 62243), the agency explicitly envisioned ASRs as the primary "active ingredients" used by sophisticated clinical laboratories to assemble in-house diagnostic tests (LDTs). An ASR provides the biological specificity—the selective biochemical recognition event—between the probe and the target analyte.

However, an ASR is defined as much by what it lacks as by what it contains. In FDA's September 2007 guidance document, Commercially Distributed Analyte Specific Reagents (ASRs): Frequently Asked Questions (issued 14 September 2007; HTML landing page marked content current as of 13 March 2018). That FAQ is nonbinding guidance, not a substitute for current 21 CFR 809.10, 809.30, and 864.4020; where the FAQ and eCFR differ, prefer eCFR. The FAQ articulates three characteristics that, in FDA's view, a product must possess to remain within 21 CFR 864.4020:

• Single-Target Specificity: The reagent must be designed and used to identify or quantify an individual, single ligand or chemical substance (e.g., a specific protein epitope, a single nucleotide alteration, or a defined viral sequence).

• Absence of Instructions and Performance Claims: The product must not be labeled, packaged, or promoted with instructions for use, assay protocols, dilution ratios, incubation times, run parameters, or statements regarding analytical or clinical performance.

• No Systemic or Instrument Exclusivity: The reagent must not be promoted for use on specific, designated automated instrumentation, or paired with proprietary software required to interpret test results.

864.4020 ASR Versus 864.4010 General-Purpose Reagent

To establish a rigorous product boundary, RA/QA teams must distinguish ASRs from General Purpose Reagents. Under 21 CFR 864.4010(a), a General Purpose Reagent is defined as:

"...a chemical reagent that has general laboratory application, that is used to collect, prepare, and examine specimens from the human body for diagnostic purposes, and that is not labeled or otherwise intended for a specific diagnostic application. It may be an individual substance or multiple substances reformulated which, when combined with or used in conjunction with an appropriate analyte specific reagent (ASR) and other general purpose reagents, is part of a diagnostic test procedure or system constituting a finished in vitro diagnostic (IVD) test."

The statutory text provides concrete illustrations of GPRs: cytological preservatives, decalcifying reagents, fixatives and adhesives, tissue processing reagents, isotonic solutions, pH buffers, and reagents used in tests for more than one individual chemical substance or ligand, such as TAQ polymerase and enzyme immunoassay (EIA) substrates. While an ASR provides analyte specificity, GPRs provide the non-specific chemical environment necessary for specimen preservation, amplification, or signal generation.

The critical regulatory firewall between ASRs and GPRs centers on cross-reagent utility and promotional isolation. According to Question 9 of FDA's 2007 ASR FAQ, GPRs are not analyte-specific and should have the potential to be combined with more than one type of ASR. If a manufacturer promotes a general reagent as specifically optimized for or dedicated to a single ASR, that reagent acquires a specific diagnostic intended use and loses its GPR classification (FAQ Question 11). Furthermore, manufacturers who market both ASRs and GPRs must not package, bundle, or sell them together as a cohesive test procedure. Bundling an ASR with GPRs effectively creates a finished IVD test system under 21 CFR 809.10(b), extinguishing the Class I 510(k) exemption.

The following matrix summarizes the fundamental operational and regulatory differences across ASRs, GPRs, investigational reagents, and finished IVD products:

Class I Exemption Versus Class II Blood-Banking or Class III HIV, TB, or Donor-Screening

A common misconception among device manufacturers is that categorizing a product as an ASR automatically secures an exemption from 510(k) premarket notification. This assumption is legally incorrect. Device classification under 21 CFR 864.4020(b) establishes a three-tiered risk structure based on the specific clinical target and public health consequences of potential misdiagnosis:

• 21 CFR 864.4020(b)(1) — Class I (General Controls): The vast majority of ASRs fall under Class I and are exempt from premarket notification under Part 807 Subpart E. These are single-ligand reagents intended for general diagnostic applications (e.g., immunohistochemistry antibodies for tumor typing, flow cytometry markers, or genetic variant probes), subject to the limitations set forth in paragraphs (b)(2) and (b)(3).

• 21 CFR 864.4020(b)(2) — Class II (Special Controls): An ASR is classified as Class II if the analyte is used in blood banking tests that have been classified as Class II devices. Common regulatory examples include cytomegalovirus (CMV) serological reagents and Treponema pallidum non-treponemal reagents used in syphilis screening. Class II ASRs are subject to FDA guidance documents, special controls, and 510(k) premarket notification.

• 21 CFR 864.4020(b)(3) — Class III (Premarket Approval / PMA): An ASR is classified as Class III and requires an approved PMA application under Section 515 of the FD&C Act if it meets either of two statutory criteria:

  1. Contagious Disease Criterion (864.4020(b)(3)(i)): The analyte is intended as a component in a test intended for use in the diagnosis of a contagious condition that is highly likely to result in a fatal outcome, where prompt and accurate diagnosis offers the opportunity to mitigate public health impact. Prime statutory examples include HIV/AIDS and active Mycobacterium tuberculosis (TB).

  2. Blood Donor Screening Criterion (864.4020(b)(3)(ii)): The analyte is intended as a component in a test intended for use in donor screening for conditions for which FDA has recommended or required testing to safeguard the blood supply or establish the safe use of blood and blood products. Prime examples include Hepatitis B virus (HBV), Hepatitis C virus (HCV), and blood group typing reagents (such as anti-A, anti-B, and anti-D).

FDA's 2007 FAQ (Question 5) explicitly clarifies that ASRs intended as components in assays for HIV diagnosis, including monitoring for viral load or detecting HIV drug resistance mutations, are considered Class III ASRs. A manufacturer cannot bypass PMA review for an HIV primer or viral load probe simply by labeling the vial as an ASR.

Furthermore, when an ASR qualifies for Class I 510(k) exemption under 864.4020(b)(1), that exemption relieves the manufacturer only of the requirement to submit a 510(k) premarket notification. It does not exempt the firm from core statutory duties under the FD&C Act. As detailed in our comprehensive guide on 510(k)-Exempt in 2026: How to Check the QMSR, Registration, and UDI Duties You Owe, Class I ASR manufacturers must maintain compliance across four surviving pillars:

1. Establishment Registration and Listing: The manufacturing facility must register annually and list every commercial ASR under 21 CFR 807.20(a).

2. Medical Device Reporting (MDR): Adverse events, product malfunctions, and deaths or serious injuries associated with the reagent must be reported under 21 CFR Part 803.

3. Strict Container Labeling: Packaging must adhere strictly to 21 CFR 809.10(e), including the mandatory statutory disclaimer.

4. Current Good Manufacturing Practice (CGMP / QMSR): Reagents must be manufactured under full 21 CFR Part 820 controls pursuant to 21 CFR 809.20(b).

flowchart TD
    Start["Reagent SKU Under Evaluation"] --> Q1{"Is reagent intended for human specimen examination? (21 CFR 809.3)"}
    Q1 -- "No" --> NonIVD["Non-IVD / Research Chemical / Veterinary
(Outside Part 809 Scope)"]
    Q1 -- "Yes" --> Q2{"Does it target an individual chemical substance or ligand? (864.4020(a))"}
    Q2 -- "No" --> Q3{"Is it a general laboratory chemical without specific diagnostic intent? (864.4010)"}
    Q3 -- "Yes" --> GPR["General Purpose Reagent (GPR)
Class I Exempt; QMSR 820.35 only if non-sterile"]
    Q3 -- "No" --> FinishedKit["Finished IVD Reagent / Kit (809.10(a)/(b))
Owes IFU and performance; premarket follows class"]
    Q2 -- "Yes" --> Q4{"Are assay instructions, protocols, or performance claims provided?"}
    Q4 -- "Yes" --> FinishedIVD["Finished IVD Component (809.10(a)/(b))
Outside ASR identity; not kept by an ASR stamp"]
    Q4 -- "No" --> Q5{"Is it bundled with GPRs, controls, software, or dedicated instruments?"}
    Q5 -- "Yes" --> FinishedIVD
    Q5 -- "No" --> ValidASR["Valid Analyte Specific Reagent (ASR)
Subject to 21 CFR 864.4020 & 809.30"]
    ValidASR --> ClassCheck{"Evaluate Analyte Target (864.4020(b))"}
    ClassCheck -- "Blood Banking Class II Analyte" --> ClassII["Class II ASR (864.4020(b)(2))
Special Controls / 510(k) Required"]
    ClassCheck -- "HIV / TB / Donor Screening" --> ClassIII["Class III ASR (864.4020(b)(3))
Premarket Approval (PMA) Required"]
    ClassCheck -- "All Other Analytes" --> ClassI["Class I ASR (864.4020(b)(1))
510(k) Exempt (MVU); Full QMSR 809.20(b)"]

809.30(b) Who May Buy This SKU, and When 809.30(g) Lifts the Rest

Under 21 CFR 809.30(a), Analyte Specific Reagents are classified as restricted devices pursuant to Section 520(e) of the FD&C Act. Because ASRs lack manufacturer-validated instructions for use and established clinical performance metrics, Congress and FDA restricted their commercial distribution exclusively to entities possessing the technical competence to independently establish assay validity. Under 21 CFR 809.30(b), ASRs may be sold only to the following three classes of purchasers:

1. In Vitro Diagnostic Manufacturers: Establishments that purchase the ASR to incorporate it as a component, raw material, or active ingredient into their own finished, legally marketed IVD test systems (21 CFR 809.30(b)(1)).

2. High-Complexity Clinical Laboratories: Clinical laboratories regulated under the Clinical Laboratory Improvement Amendments of 1988 (CLIA, 42 CFR part 493) as qualified to perform high complexity testing, or clinical laboratories regulated under Veterans Health Administration (VHA) Directive 1106 (21 CFR 809.30(b)(2)).

3. Nonclinical and Non-Diagnostic Organizations: Organizations that use the reagents to manufacture tests for purposes other than providing diagnostic information to patients and practitioners, such as forensic, academic, research, environmental, or other nonclinical laboratories (21 CFR 809.30(b)(3)).

Sales to any other entity—including moderate-complexity laboratories, waived laboratories, physician office laboratories (POLs) not certified for high complexity, pharmacies, clinics, or direct-to-consumer buyers—are strictly prohibited by federal law. Selling an ASR to a physician office lab lacking high-complexity CLIA accreditation violates Section 502(q) of the FD&C Act.

The second crucial half of Section 809.30 is paragraph (g), which creates an operational carve-out for non-clinical and manufacturer transactions. Under 21 CFR 809.30(g), the restrictions in paragraphs (c) through (f) of this section do not apply when reagents that otherwise meet the ASR definition are sold to in vitro diagnostic manufacturers, or to organizations that use the reagents to make tests for purposes other than providing diagnostic information to patients and practitioners.

"The restrictions in paragraphs (c) through (f) of this section do not apply when reagents that otherwise meet the ASR definition are sold to in vitro diagnostic manufacturers, or to organizations that use the reagents to make tests for purposes other than providing diagnostic information to patients and practitioners..."

This provision aligns perfectly with 21 CFR 864.4020(a)(1) and (a)(2), which explicitly state that ASRs sold to IVD manufacturers or nonclinical testing facilities are not within the scope of Part 864 Subpart E.

Regulatory affairs teams must precisely understand the mechanics of 809.30(g):

• What 809.30(g) Lifts: When selling to another IVD manufacturer or to a nonclinical/forensic lab, the seller is relieved of: (c) the mandatory 809.10(e) container statement; (d) advertising and promotional copy restrictions; (e) downstream laboratory report disclaimer rules; and (f) practitioner ordering restrictions.

• What 809.30(g) Does NOT Lift: Paragraph (g) does not lift paragraph (b). The purchaser must still strictly belong to permitted classes (1) or (3). Selling an ASR to an unauthorized buyer cannot be defended by citing paragraph (g).

• No Conversion to RUO: Selling an ASR to a university research laboratory under 809.30(b)(3) and 809.30(g) does not convert the product into an RUO reagent under 21 CFR 809.10(c)(2). It remains an ASR, manufactured under appropriate quality controls, with commercial distribution restricted by federal law.

Four Labeling Families Are Not Interchangeable

In vitro diagnostic labeling regulations under 21 CFR Part 809 establish four separate, mutually exclusive labeling families for chemical and biological reagents. A product SKU can carry only one labeling family. Blending elements from different families—such as placing an ASR statement alongside instructions for use, or adding an RUO disclaimer to a clinically distributed finished reagent—creates immediate regulatory non-compliance.

1. Analyte Specific Reagent Labeling (21 CFR 809.10(e)): The container label must display the proprietary name, common name, quantity, purity and quality, warnings, date of manufacture and storage instructions, net contents, manufacturer identity, and lot number. 809.10(e)(1)(iv) also permits specified scientific composition information, including nucleic acid sequence, binding affinity, and cross-reactivity, without converting those facts into assay instructions. Most critically, the label must display the verbatim statutory disclaimer:

• For Class I ASRs (809.10(e)(1)(x)): "Analyte Specific Reagent. Analytical and performance characteristics are not established."

• For Class II and Class III ASRs (809.10(e)(1)(xi)): "Analyte Specific Reagent. Except as a component of the approved/cleared test (Name of approved/cleared test), analytical and performance characteristics of this ASR are not established."

2. Finished IVD Product Labeling (21 CFR 809.10(a) and (b)): Finished IVDs are designed for direct clinical diagnostic utility. They must prominently bear the statement "For In Vitro Diagnostic Use" and include a comprehensive package insert detailing: intended use, clinical indications, specimen collection and preparation, step-by-step assay procedures, required instrumentation, calibration and quality control procedures, limitations of the procedure, and fully documented analytical and clinical performance characteristics (limit of detection, linearity, precision, cross-reactivity, clinical sensitivity, and clinical specificity).

3. Investigational Reagent Labeling (21 CFR 809.10(c)(2)): Shipments intended strictly for investigational or research evaluation are governed by 809.10(c)(2). As examined in our guide on RUO vs IUO vs IVD Labeling: Research, Investigational, and Diagnostic Boundaries, these reagents are divided into two categories:

• Research Use Only (RUO, 809.10(c)(2)(i)): For products in the laboratory research phase: "For Research Use Only. Not for use in diagnostic procedures."

• Investigational Use Only (IUO, 809.10(c)(2)(ii)): For a shipment or delivery for an investigation that is not subject to 21 CFR part 812, when the product is being shipped or delivered for product testing prior to full commercial marketing: "For Investigational Use Only. The performance characteristics of this product have not been established."

809.10(c)(2) RUO and IUO statements are investigational-shipment identity for investigations not subject to part 812. They are not 809.30(b)(2) sale permission to a CLIA high-complexity laboratory, and they are not 809.10(e) ASR labeling. A shipment for an investigation that is subject to part 812 is the separate 809.10(c)(1) field. An RUO or IUO statement does not authorize routine patient diagnostic reporting.

4. General Purpose Laboratory Reagents (21 CFR 809.10(d)): Reagents with general laboratory utility must bear the statement "For Laboratory Use." They are exempt from the step-by-step directions for use required under paragraphs (a) and (b) if their procedures and general applications are already known to laboratory practitioners.

Promotion, Instructions, Software, and Designated Instruments

The statutory restrictions governing advertising and promotional materials for ASRs are codified in 21 CFR 809.30(d). Promotional materials, marketing brochures, digital catalog listings, and scientific spec sheets must include: (1) the identity and purity of the ASR (including biological source and method of acquisition); (2) the identity of the target analyte; and (3) the exact statutory disclaimer mandated for Class I or Class II/III products. Under 21 CFR 809.30(d)(4), promotional materials "shall not make any statement regarding analytical or clinical performance."

In daily commercial operations, marketing and sales teams frequently cross the line between permitted technical specifications and prohibited promotional claims. FDA's September 2007 ASR FAQ provides detailed administrative guidance on practices that take a reagent outside the ASR definition:

• Handling Instructions vs Assay Protocols: Under 21 CFR 809.10(e)(1)(vi), manufacturers are required to provide instructions for storage and handling (e.g., storage at -20°C, avoid repeated freeze-thaw cycles, reconstitution in sterile deionized water). However, providing instructions on how to develop, validate, or perform an assay (e.g., recommended incubation times, wash protocols, antibody titers, or sample dilution ratios) takes the product outside the ASR classification (FAQ Question 12).

• Target Naming vs Clinical Disease Association: The promotional material must identify the analyte or target ligand using descriptive biochemical nomenclature (e.g., 'anti-estrogen receptor antibody' or 'ΔF508 CFTR nucleic acid probe'). Promotional titles that tie the reagent to a clinical disease, diagnosis, or risk stratification—such as 'Cardiac Risk ASR' or 'Alzheimer's Diagnostic Marker'—constitute clinical performance claims that dismantle ASR exemption (FAQ Question 13).

• Bundled Cocktails and Multiplex Panels: Combining multiple ASRs into a single pre-mixed vial or pre-configured panel (such as a multi-color flow cytometry panel or multiplex PCR primer cocktail) takes the product outside the ASR definition in FDA's 2007 FAQ Section II / Question 8. That FAQ row is guidance beside 864.4020. Multiple targets require multiple independent validation decisions by the clinical laboratory.

• Designated Automated Instrumentation: Manufacturers must not promote an ASR for use on specific, designated laboratory instruments. Reagents designed with proprietary barcoded cartridges or proprietary containers that can only operate on a specific closed analyzer are treated as components of a closed IVD test system. Conversely, open-architecture instruments featuring user-definable programming may be marketed generally for laboratory use, provided they are not cross-promoted with specific ASRs (FAQ Questions 15 and 16).

• Proprietary Interpretive Software: Offering an ASR in conjunction with algorithmic software designed to analyze raw data, calculate diagnostic indices, or provide diagnostic interpretations extinguishes ASR status. Standalone interpretive software intended for diagnostic applications is itself a medical device subject to premarket review (FAQ Question 15).

• Calibrators and External Controls: Quality control materials are not ASRs. FAQ Question 14 states that an ASR manufacturer may supply QC materials, but should promote them independently of a specific ASR and under existing QC classifications (for example 21 CFR 862.1660, 862.3280, or 864.8625). Marketing those materials for use with a particular ASR can take the combination outside 864.4020. That FAQ row is guidance; it is not a rule that every QC material or calibrator independently requires 510(k) clearance.

809.30(e) Laboratory-Report Language Is Not Manufacturer Clearance

When a CLIA-regulated high-complexity laboratory purchases an ASR to assemble an in-house laboratory-developed test (LDT), the laboratory assumes direct regulatory responsibility for establishing assay performance. Under 21 CFR 809.30(e), the clinical laboratory must append a specific statutory disclaimer to every patient test report:

"This test was developed and its performance characteristics determined by (Laboratory Name). It has not been cleared or approved by the U.S. Food and Drug Administration."

The regulation carves out an explicit exception: this report disclaimer is not applicable or required when test results are generated using a test that was cleared (510(k)) or approved (PMA) in conjunction with review of a Class II or Class III ASR. In addition, under 21 CFR 809.30(f), clinical tests developed using ASRs may be ordered only by physicians and other licensed healthcare practitioners authorized under applicable state law.

A dangerous misconception among commercial reagent suppliers is that a clinical laboratory's successful validation of an LDT confers regulatory clearance or validation upon the underlying ASR. It does not. The regulatory lines between manufacturer and testing laboratory must be strictly maintained:

• No Derivative Clearance: A laboratory's analytical validation of an LDT under CLIA is specific to that laboratory's standard operating procedure, patient population, and instrument configuration. It does not validate the manufacturer's ASR for general commercial marketing.

• Prohibition on Manufacturer Assistance: According to Question 17 of FDA's 2007 FAQ, an ASR manufacturer must not assist a clinical laboratory with the development, clinical optimization, or validation of an LDT using that specific ASR. Providing on-site assay development, protocol templates, or clinical validation data converts the relationship into joint commercial distribution of an unapproved finished test.

• Current CLIA Validation Citations: In the historical 2007 ASR FAQ, FDA referenced 42 CFR 493.1213 for laboratory analytical validation. That citation is obsolete. Under current CLIA regulations, clinical laboratories establish performance specifications for in-house tests (accuracy, precision, analytical sensitivity, analytical specificity, reportable range, and reference intervals) pursuant to 42 CFR 493.1253.

ASR Manufacture Under 809.20(b) Is Not the GPR QMSR Remainder

The manufacturing quality standards governing Analyte Specific Reagents differ fundamentally from those governing General Purpose Reagents. Under 21 CFR 809.20(b):

"In vitro diagnostic products shall be manufactured in accordance with the good manufacturing practices requirements found in part 820 of this chapter and, if applicable, § 610.44 of this chapter."

On February 2, 2026, FDA's Quality Management System Regulation (QMSR) final rule took full effect, incorporating ISO 13485:2016 by reference with FDA-specific additions in 21 CFR part 820. Because product-code MVU is listed as 'GMP Exempt? No', and because 21 CFR 809.20(b) requires IVD products to be manufactured in accordance with part 820, ASR manufacturers must comply with that part 820 QMSR. Compliance with QMSR is not a requirement to hold a third-party ISO 13485 certificate. 21 CFR 820.35 is the control-of-records remainder; it is not the entire QMSR and it is not the 864.4010(b) GPR exemption.

In contrast, General Purpose Reagents benefit from a substantial statutory carve-out. Under 21 CFR 864.4010(b), if a GPR is not labeled or otherwise represented as sterile, it is exempt from the good manufacturing practice requirements of Part 820 except for control of records and complaint files under 21 CFR 820.35. This cross-reference was formally codified in the Federal Register at 90 FR 55981 (December 4, 2025) as part of the QMSR Technical Amendments, effective February 2, 2026. However, if a GPR is represented as sterile, this exemption vanishes, and full sterility assurance and quality controls apply.

Finally, RA/QA teams must avoid the dangerous assumption that Research Use Only (RUO) status provides an easy manufacturing shortcut. While FDA's 2007 FAQ (Question 21) states, as guidance, that the agency does not expect reagents strictly labeled for research use under 809.10(c)(2)(i) to comply with Part 820 CGMPs, RUO reagents cannot be lawfully sold for clinical diagnostic use. FAQ Q21 is not 809.30(b)(2) sale permission, and it is not permission to sell a clinical diagnostic reagent under an RUO label.

Labeled Boundaries This Worksheet Does Not Decide

To prevent regulatory scope creep, compliance teams must establish explicit boundaries around the 21 CFR 809.30 ASR decision. This worksheet evaluates single-reagent commercial distribution in the US; it does not resolve seven adjacent regulatory domains:

• Over-The-Counter Drugs of Abuse Collection Systems (21 CFR 809.40): OTC test sample collection systems for drugs of abuse are separate restricted devices under Section 520(e), governed by 21 CFR 809.40, classified under 21 CFR 864.3260, and labeled under 21 CFR 809.10(f). They are entirely separate from ASR rules.

• Veterinary Diagnostic Reagents: 21 CFR Part 809 applies strictly to in vitro diagnostic products intended for human specimens. Veterinary diagnostic reagents are regulated under the FDA Center for Veterinary Medicine (CVM) and the USDA Animal and Plant Health Inspection Service (APHIS).

• CLIA Laboratory Performance Establishment (42 CFR 493.1253): The clinical laboratory's internal validation protocol for an LDT is a CLIA obligation, not an FDA device manufacturing duty.

• European Union In-House Exemption (IVDR Article 5(5)): Health institution in-house manufacturing under EU IVDR 2017/746 operates under distinct European legal requirements (such as justification of unmet need and CE-marking prerequisites) that do not apply to US ASRs.

• Leftover-Sample Clinical Studies (21 CFR 812.2(c)(3)): Protocol exemptions for diagnostic investigations utilizing leftover, de-identified human specimens are governed by IDE regulations, as detailed in our guide on Does This US IVD Study Need an IDE, an IND, or Neither?.

• Companion Diagnostics (CDx) Pathways: IVDs designed to identify patients likely to benefit from a specific therapeutic drug are companion-diagnostic marketing-pathway decisions, not 809.30 identity. Do not recast them here.

• General Exemption Limitations Under 21 CFR 864.9: While 21 CFR 864.4010(b) explicitly subjects GPR 510(k) exemptions to the general limitations in 21 CFR 864.9, ASR classification is governed specifically by the statutory categories in 21 CFR 864.4020(b)(1)–(3).

• Manufacturer LoD, LoQ, and precision evidence for a finished IVD: Analytical-performance protocols for a finished IVD are a different worksheet, not 809.30 identity. See IVD Analytical Performance Validation: LoD, LoQ, Precision and Stability.

Mark One Labeled Fictional Label-and-Promotion Packet

To demonstrate the operational application of this worksheet, we evaluate a fully realized, labeled fictional reagent SKU. This sample packet illustrates how RA/QA teams must audit physical container labels, package inserts, and promotional collateral to verify compliance:

SKU Under Evaluation: BioReceptor Monoclonal Anti-EGFR-T790M Reagent (Catalog # BR-EGFR-790, Fictional)

Physical Product Formulation: 1.0 mL glass vial containing 0.5 mg/mL purified murine monoclonal antibody (clone T790M-X42) in 10 mM phosphate-buffered saline (PBS), pH 7.4, with 0.05% sodium azide. Specific binding affinity to human EGFR T790M peptide characterized by surface plasmon resonance (Kd = 1.2 x 10^-9 M). No secondary antibodies, chromogens, enzymes, or run buffers included.

Identity-field audit of the fictional SKU:

Negative Failure Scenario: What Destroys This ASR Status?

Consider what occurs if the manufacturer's commercial marketing team modifies the catalog listing to state:

"Optimized for automated immunohistochemistry detection of EGFR T790M resistance in non-small cell lung cancer biopsies on the AutoStainer-X system. Dilute 1:100, incubate 45 minutes at room temperature. Demonstrates 98% clinical sensitivity and 99% clinical specificity."

The moment this promotional text is published, the SKU instantly loses its ASR classification. The product now contains specific procedural instructions for use, clinical disease associations, closed instrumentation requirements, and explicit clinical performance claims. In FDA's 2007 ASR FAQ, those marketing practices take the product outside 864.4020. The FAQ is guidance, not a substitute for current 809.10, 809.30, and 864.4020. Once assay instructions or analytical or clinical performance are claimed, treat the SKU as a finished IVD that owes 809.10(a) and (b), not as an ASR that remains 510(k) exempt because an ASR statement is still printed. Premarket identity then follows the finished product's class and intended use—510(k), PMA, or another applicable pathway—not a rule that an ASR stamp keeps it class I. This labeled fiction has no 510(k) or PMA number; it is not a finding that every finished IVD is adulterated under section 501(f)(1)(B) and misbranded under section 502(o).

This worksheet is not the published RUO/IUO labeling encyclopedia, not RUO-to-IVD conversion, not the LDT vacatur page, not yesterday's leftover-sample IDE-versus-IND worksheet, not CLIA 493.1253 verification of a marketed unmodified test, and not IVDR Article 5(5) in-house manufacture. Link those hubs; do not recast them:

• RUO vs IUO vs IVD Labeling: Research, Investigational, and Diagnostic Boundaries — labeling-family encyclopedia, not this 809.30 identity worksheet.

• RUO-to-IVD Conversion Firewall: Convert Research-Use Assays Without Evidence Risk — conversion of a research-use assay, not ASR purchaser or class rows.

• LDT Regulatory Guide: FDA 2024 Rule Vacatur, CLIA Oversight, and Next Steps — laboratory LDT policy after vacatur, not manufacturer 510(k) of an ASR.

• In Vitro Diagnostic (IVD) Devices: The Complete Regulatory Guide for FDA and EU IVDR — IVD encyclopedia, including Part 809 at overview level.

• IVD Registration Compared: FDA 809, EU IVDR, China, Brazil & India — multi-jurisdiction registration comparison.

• CLIA Waiver for IVDs: Submission Strategy, Study Design, and Dual 510(k) Pathway — dual 510(k)/CLIA-waiver submission, not 809.30(b)(2).

• Does This US IVD Study Need an IDE, an IND, or Neither? — leftover-sample IDE versus IND, not this SKU identity.

• Companion Diagnostics (CDx): Regulatory Pathways, Development, and Market Access — CDx marketing pathways, not ASR class III identity.

• IVD Analytical Performance Validation: LoD, LoQ, Precision and Stability — manufacturer LoD/LoQ/precision evidence for a finished IVD.

• 510(k)-Exempt in 2026: How to Check the QMSR, Registration, and UDI Duties You Owe — surviving duties after a 510(k) skip, not 864.4020(b) class rows.

• Medical Device Labeling & UDI System: The Complete Regulatory Guide — UDI encyclopedia, not 809.10(e) versus 809.10(a)/(b).

• Veterinary Medical Device Regulation: FDA CVM, EU Gaps, and Global Strategy — CVM veterinary identity, outside part 809.

• QMSR Gap Analysis for ISO 13485 Companies: 50+ Item Checklist — QMSR-to-ISO 13485 mapping, not the GPR 820.35 remainder.

• Point-of-Care Testing (POCT): Regulatory Requirements, CLIA Waivers, and Market Trends — POCT pathways, not ASR purchaser limits.

• Home-Use IVD Invalid Result Workflow for Consumer Diagnostics — home-use invalid-result workflow, not 809.30.